Novel Treatments of Strong Correlations, Volume 90 in the Advances in Quantum Chemistry series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. Topics covered include Coupled Cluster, Stochastic CC, NOFT, Breaking the Symmetry Dilemma : Capturing Strong-Correlations by Restoration of Broken Symmetry Solutions, Flexible wavefunctions, Electronic Coupling to Optical Cavity Modes, Multireference Perturbation Theories Based on the Dyall Hamiltonian, The GW Approximation: A Quantum Chemistry Perspective, Geminals, and more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in Advances in Quantum Chemistry series - Updated release includes the latest information on this timely topic

This book offers a new approach to the long-standing problem of high-Tc copper-oxide superconductors. It has been demonstrated that starting from a strongly correlated Hamiltonian, even within the mean-field regime, the “competing orders” revealed by experiments can be achieved using numerical calculations. In the introduction, readers will find a brief review of the high-Tc problem and the unique challenges it poses, as well as a comparatively simple numerical approach, the renormalized mean-field theory (RMFT), which provides rich results detailed in the following chapters. With an additional phase picked up by the original Hamiltonian, some behaviors of interactive fermions under an external magnetic field, which have since been experimentally observed using cold atom techniques, are also highlighted.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

The new Animal Genetics and Disease 2017 conference committee organized a Research Topic for the proceedings of this inaugural conference. The meeting brought together specialists working on the interface between genomics, genetic engineering, and infectious disease, with the aims of improving animal and human health and welfare. This conference was funded by Advanced Courses and Scientific Conference at the Wellcome Genome Campus, Hinxton, UK. The conference will highlight breakthroughs in genomic technologies that are rapidly increasing our understanding of the fundamental role that host and pathogen genetics play in infections and epidemics. This Research Topic focuses on how infections spread and how they further affect the productivity of livestock systems and food supply chains. Thanks to technological advances, we now have the tools for real-time surveillance of zoonoses affecting wildlife, farm animals and animal-to-human disease transmission.

Asthma, allergy and chronic obstructive lung disease are common throughout the world and are increasing in incidence, particularly in the developing world. This volume provides a state-of-the-art account of the identification of new targets and the development of new therapies for these conditions. Some 40 chapters by clinical academics and senior members of the pharmaceutical industry detail the latest breakthroughs in research and development. In asthma, a promising approach is the use of therapy directed against specific Th2 responses through biological antagonists of IL-5, IL-4 and IL-13. There have also been major advances in our understanding of innate immune responses to pathogen-associated molecular patterns, and in the area of Toll-like receptors. Up to date and comprehensive, this book will be of particular relevance to those working in the pharmaceutical industry (in preclinical research and clinical development), to academic researchers in the field of respiratory medicine, and to respiratory health care specialists.